At 47th AUGS Annual Scientific Meeting, Medtronic advances AltavivaTM clinical program with 24-month exploratory findings from TITAN 2 showing sustained reductions in nightly nocturia episodes and announces partnership to advance patient awareness of pelvic floor disorders Medtronic the global leader in healthcare technology today announced new updates, including clinical evidence, for the Altaviva™ implantable tibial neuromodulation device at AUGS 2026, reinforcing [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.